Tenvie Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Tenvie Therapeutics's estimated annual revenue is currently $5M per year.
- Tenvie Therapeutics's estimated revenue per employee is $155,000
- Tenvie Therapeutics's total funding is $200M.
Employee Data
- Tenvie Therapeutics has 32 Employees.
- Tenvie Therapeutics grew their employee count by 191% last year.
Tenvie Therapeutics's People
| Name | Title | Email/Phone |
|---|
Tenvie Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is Tenvie Therapeutics?
Tenvie is a biotechnology company committed to engineering small molecules that transform the treatment of neurological diseases. The company’s foundation is purpose-built with a diverse portfolio of small molecules and a proven team of CNS drug developers to rapidly deliver multiple clinical assets. Tenvie is advancing a pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases. Its portfolio of wholly owned, highly brain-penetrant, and precision-designed peripherally restricted small molecules address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function.
keywords:N/A
$200M
Total Funding
32
Number of Employees
$5M
Revenue (est)
191%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.7M | 32 | -22% | N/A |
#2 | $4M | 32 | -26% | $71.2M |
#3 | $3.4M | 32 | -11% | $124M |
#4 | $5M | 32 | -48% | $29.6M |
#5 | $3.4M | 32 | -24% | $21.3M |